13 min

Cost-effectiveness of Aflibercept vs Bevacizumab-First Therapy for Diabetic Macular Edema JAMA Ophthalmology Author Interviews

    • Medicine

Interview with David W. Hutton, PhD, author of Cost-effectiveness of Aflibercept Monotherapy vs Bevacizumab First Followed by Aflibercept If Needed for Diabetic Macular Edema. Hosted by Neil Bressler, MD.

  • American Medical Association, 2020

Interview with David W. Hutton, PhD, author of Cost-effectiveness of Aflibercept Monotherapy vs Bevacizumab First Followed by Aflibercept If Needed for Diabetic Macular Edema. Hosted by Neil Bressler, MD.

13 min

  • American Medical Association, 2020

More by JAMA Network

JAMA Medical News
JAMA Medical News
JAMA Network
JAMA Otolaryngology–Head & Neck Surgery Author Interviews
JAMA Otolaryngology–Head & Neck Surgery Author Interviews
JAMA Network
JAMA Psychiatry Author Interviews
JAMA Psychiatry Author Interviews
JAMA Network
JAMA Clinical Reviews
JAMA Clinical Reviews
JAMA Network
JAMAevidence JAMA Guide to Statistics and Methods
JAMAevidence JAMA Guide to Statistics and Methods
JAMA Network
JAMA Surgery Editors' Summary
JAMA Surgery Editors' Summary
JAMA Network